BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 28287644)

  • 1. Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation.
    Dotoli GM; De Santis GC; Orellana MD; de Lima Prata K; Caruso SR; Fernandes TR; Rensi Colturato VA; Kondo AT; Hamerschlak N; Simões BP; Covas DT
    Bone Marrow Transplant; 2017 Jun; 52(6):859-862. PubMed ID: 28287644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesenchymal Stromal Cells for Treatment of Acute Steroid-Refractory Graft Versus Host Disease: Clinical Responses and Long-Term Outcome.
    von Dalowski F; Kramer M; Wermke M; Wehner R; Röllig C; Alakel N; Stölzel F; Parmentier S; Sockel K; Krech M; Schmitz M; Platzbecker U; Schetelig J; Bornhäuser M; von Bonin M
    Stem Cells; 2016 Feb; 34(2):357-66. PubMed ID: 26418955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation.
    Zhao K; Lou R; Huang F; Peng Y; Jiang Z; Huang K; Wu X; Zhang Y; Fan Z; Zhou H; Liu C; Xiao Y; Sun J; Li Y; Xiang P; Liu Q
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):97-104. PubMed ID: 25300866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
    Keklik M; Deveci B; Celik S; Deniz K; Gonen ZB; Zararsiz G; Saba R; Akyol G; Ozkul Y; Kaynar L; Keklik E; Unal A; Cetin M; Jones OY
    Ann Hematol; 2023 Jun; 102(6):1537-1547. PubMed ID: 37067556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease.
    Ball LM; Bernardo ME; Roelofs H; van Tol MJ; Contoli B; Zwaginga JJ; Avanzini MA; Conforti A; Bertaina A; Giorgiani G; Jol-van der Zijde CM; Zecca M; Le Blanc K; Frassoni F; Egeler RM; Fibbe WE; Lankester AC; Locatelli F
    Br J Haematol; 2013 Nov; 163(4):501-9. PubMed ID: 23992039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Mesenchymal Stem Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease following Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
    Chen X; Wang C; Yin J; Xu J; Wei J; Zhang Y
    PLoS One; 2015; 10(8):e0136991. PubMed ID: 26323092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study.
    Prasad VK; Lucas KG; Kleiner GI; Talano JA; Jacobsohn D; Broadwater G; Monroy R; Kurtzberg J
    Biol Blood Marrow Transplant; 2011 Apr; 17(4):534-41. PubMed ID: 20457269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequential third-party mesenchymal stromal cell therapy for refractory acute graft-versus-host disease.
    Sánchez-Guijo F; Caballero-Velázquez T; López-Villar O; Redondo A; Parody R; Martínez C; Olavarría E; Andreu E; Prósper F; Díez-Campelo M; Regidor C; Villaron E; López-Corral L; Caballero D; Cañizo MC; Pérez-Simon JA
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1580-5. PubMed ID: 24952358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease.
    van Groningen LF; Liefferink AM; de Haan AF; Schaap NP; Donnelly JP; Blijlevens NM; van der Velden WJ
    Biol Blood Marrow Transplant; 2016 Jan; 22(1):179-82. PubMed ID: 26386320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients.
    Kurtzberg J; Prockop S; Teira P; Bittencourt H; Lewis V; Chan KW; Horn B; Yu L; Talano JA; Nemecek E; Mills CR; Chaudhury S
    Biol Blood Marrow Transplant; 2014 Feb; 20(2):229-35. PubMed ID: 24216185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation.
    Minculescu L; Kornblit BT; Friis LS; Schiødt I; Petersen SL; Andersen NS; Sengeloev H
    Biol Blood Marrow Transplant; 2018 Mar; 24(3):600-607. PubMed ID: 29074374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation.
    Khandelwal P; Emoto C; Fukuda T; Vinks AA; Neumeier L; Dandoy CE; El-Bietar J; Chandra S; Davies SM; Bleesing JJ; Jordan MB; Mehta PA; Jodele S; Grimley MS; Kumar A; Myers KC; Marsh RA
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2220-2225. PubMed ID: 27664325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of graft versus host disease with mesenchymal stromal cells: a phase I study on 40 adult and pediatric patients.
    Introna M; Lucchini G; Dander E; Galimberti S; Rovelli A; Balduzzi A; Longoni D; Pavan F; Masciocchi F; Algarotti A; Micò C; Grassi A; Deola S; Cavattoni I; Gaipa G; Belotti D; Perseghin P; Parma M; Pogliani E; Golay J; Pedrini O; Capelli C; Cortelazzo S; D'Amico G; Biondi A; Rambaldi A; Biagi E
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):375-81. PubMed ID: 24321746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study.
    Herrmann R; Sturm M; Shaw K; Purtill D; Cooney J; Wright M; Phillips M; Cannell P
    Int J Hematol; 2012 Feb; 95(2):182-8. PubMed ID: 22183779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study.
    Muroi K; Miyamura K; Okada M; Yamashita T; Murata M; Ishikawa T; Uike N; Hidaka M; Kobayashi R; Imamura M; Tanaka J; Ohashi K; Taniguchi S; Ikeda T; Eto T; Mori M; Yamaoka M; Ozawa K
    Int J Hematol; 2016 Feb; 103(2):243-50. PubMed ID: 26608364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM).
    Bader P; Kuçi Z; Bakhtiar S; Basu O; Bug G; Dennis M; Greil J; Barta A; Kállay KM; Lang P; Lucchini G; Pol R; Schulz A; Sykora KW; von Luettichau I; Herter-Sprie G; Uddin MA; Jenkin P; Alsultan A; Buechner J; Stein J; Kelemen A; Jarisch A; Soerensen J; Salzmann-Manrique E; Hutter M; Schäfer R; Seifried E; Klingebiel T; Bonig H; Kuçi S
    Bone Marrow Transplant; 2018 Jul; 53(7):852-862. PubMed ID: 29379171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Children and Adults with Refractory Acute Graft-versus-Host Disease Respond to Treatment with the Mesenchymal Stromal Cell Preparation "MSC-FFM"-Outcome Report of 92 Patients.
    Bonig H; Kuçi Z; Kuçi S; Bakhtiar S; Basu O; Bug G; Dennis M; Greil J; Barta A; Kállay KM; Lang P; Lucchini G; Pol R; Schulz A; Sykora KW; Teichert von Luettichau I; Herter-Sprie G; Ashab Uddin M; Jenkin P; Alsultan A; Buechner J; Stein J; Kelemen A; Jarisch A; Soerensen J; Salzmann-Manrique E; Hutter M; Schäfer R; Seifried E; Paneesha S; Novitzky-Basso I; Gefen A; Nevo N; Beutel G; Schlegel PG; Klingebiel T; Bader P
    Cells; 2019 Dec; 8(12):. PubMed ID: 31817480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastrointestinal acute graft-versus-host disease in children: histology for diagnosis, mesenchymal stromal cells for treatment, and biomarkers for prediction of response.
    Calkoen FG; Jol-van der Zijde CM; Mearin ML; Schweizer JJ; Jansen-Hoogendijk AM; Roelofs H; van Halteren AG; Egeler RM; van Tol MJ; Ball LM
    Biol Blood Marrow Transplant; 2013 Nov; 19(11):1590-9. PubMed ID: 23994245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesenchymal stromal cells plus basiliximab improve the response of steroid-refractory acute graft-versus-host disease as a second-line therapy: a multicentre, randomized, controlled trial.
    Fu H; Sun X; Lin R; Wang Y; Xuan L; Yao H; Zhang Y; Mo X; Lv M; Zheng F; Kong J; Wang F; Yan C; Han T; Chen H; Chen Y; Tang F; Sun Y; Chen Y; Xu L; Liu K; Zhang X; Liu Q; Huang X; Zhang X
    BMC Med; 2024 Feb; 22(1):85. PubMed ID: 38413930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease: a phase I/II study.
    Muroi K; Miyamura K; Ohashi K; Murata M; Eto T; Kobayashi N; Taniguchi S; Imamura M; Ando K; Kato S; Mori T; Teshima T; Mori M; Ozawa K
    Int J Hematol; 2013 Aug; 98(2):206-13. PubMed ID: 23860964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.